Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase

Methods in Enzymology

Volumn 511, Issue , 2012, Pages 463-483

  Hanson, Alicia M ^a   Hernandez, John J ^a   Shadrick, William R ^a   Frick, David N ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENZYME INHIBITOR; HELICASE; HELICASE INHIBITOR; NS3 HELICASE; NUCLEIC ACID; OLIGONUCLEOTIDE; RNA; UNCLASSIFIED DRUG;

CATALYSIS; CONCENTRATION (PARAMETERS); DNA STRAND; DRUG TARGETING; ENZYME ASSAY; ENZYME PURIFICATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPATITIS C; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR BEACON BASED HELICASE ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SPLIT BEACON HELICASE ASSAY;

HEPATITIS C VIRUS;

EID: 84862994750     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396546-2.00021-8     Document Type: Chapter

References (56)

1. Aggarwal, M., Sommers, J. A., Shoemaker, R. H., and Brosh, R. M. J. (2011). Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl. Acad. Sci. USA 108, 1525-1530.
2. Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., Burroughs, M., Brass, C. A., et al. (2011). Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217.
3. Belon, C. A., and Frick, D. N. (2008). Monitoring helicase activity with molecular beacons. Biotechniques 45(433-40), 442.
4. Belon, C. A., and Frick, D. N. (2009a). Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol. 4, 277-293.
5. Belon, C. A., and Frick, D. N. (2009b). Fuel specificity of the hepatitis C virus NS3 helicase. J. Mol. Biol. 388, 851-864.
6. Belon, C., and Frick, D. N. (2010). Thioflavin S inhibits hepatitis C virus RNA replication and the viral helicase with a novel mechanism. FASEB J. 24, lb202.
7. Belon, C. A., and Frick, D. N. (2011). NS3 helicase inhibitors. In "Hepatitis C: Antiviral Drug Discovery and Development," (Y. He and S. L. Tan, eds.), pp. 327-356. Caister Academic Press, Norfolk, UK.
8. Belon, C. A., High, Y. D., Lin, T. I., Pauwels, F., and Frick, D. N. (2010). Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. Biochemistry 49, 1822-1832.
9. Beran, R. K., Serebrov, V., and Pyle, A. M. (2007). The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J. Biol. Chem. 282, 34913-34920.
10. Beran, R. K., Lindenbach, B. D., and Pyle, A. M. (2009). The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J. Virol. 83, 3268-3275.
11. Bjornson, K. P., Amaratunga, M., Moore, K. J., and Lohman, T. M. (1994). Single-turnover kinetics of helicase-catalyzed DNA unwinding monitored continuously by fluorescence energy transfer. Biochemistry 33, 14306-14316.
12. Boger, D. L., and Tse, W. C. (2001). Thiazole orange as the fluorescent intercalator in a high resolution fid assay for determining DNA binding affinity and sequence selectivity of small molecules. Bioorg. Med. Chem. 9, 2511-2518.
13. Boger, D. L., Fink, B. E., Brunette, S. R., Tse, W. C., and Hedrick, M. P. (2001). A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity. J. Am. Chem. Soc. 123, 5878-5891.
14. Boguszewska-Chachulska, A. M., Krawczyk, M., Stankiewicz, A., Gozdek, A., Haenni, A. L., and Strokovskaya, L. (2004). Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett. 567, 253-258.
15. Borowski, P., Mueller, O., Niebuhr, A., Kalitzky, M., Hwang, L. H., Schmitz, H., Siwecka, M. A., and Kulikowsk, T. (2000). ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim. Pol. 47, 173-180.
16. Briguglio, I., Piras, S., Corona, P., and Carta, A. (2011). Inhibition of RNA Helicases of ssRNA Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families. Int. J. Med. Chem. 2011. Article ID 213135, 22 pages.
17. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362.
18. Crute, J. J., Grygon, C. A., Hargrave, K. D., Simoneau, B., Faucher, A. M., Bolger, G., Kibler, P., Liuzzi, M., and Cordingley,M. G. (2002). Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8, 386-391.
19. Edlin, B. R. (2011). Perspective: Test and treat this silent killer. Nature 474, S18-S19.
20. Frick, D. N. (2003). Helicases as antiviral drug targets. Drug News Perspect. 16, 355-362.
21. Frick, D. N. (2006). HCV helicase: Structure, function, and inhibition. In "Hepatitis C Viruses: Genomes and Molecular Biology," (S. L. Tan, ed.).Horizon Bioscience, Norfolk (UK) Chapter 7.
22. Frick, D. N. (2007). The hepatitis C virus NS3 protein: A model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 9, 1-20.
23. Frick, D. N., and Lam, A. M. (2006). Understanding helicases as a means of virus control. Curr. Pharm. Des. 12, 1315-1338.
24. Frick, D. N., Rypma, R. S., Lam, A. M., and Gu, B. (2004). The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J. Biol. Chem. 279, 1269-1280.
25. Frick, D. N., Banik, S., and Rypma, R. S. (2007). Role of divalent metal cations in ATP hydrolysis catalyzed by the hepatitis C virus NS3 helicase: Magnesium provides a bridge for ATP to fuel unwinding. J. Mol. Biol. 365, 1017-1032.
26. Frick, D. N., Ginzburg, O., and Lam, A. M. (2010). A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities. Methods Mol. Biol. 587, 223-233.
27. Hao, W., Herlihy, K. J., Zhang, N. J., Fuhrman, S. A., Doan, C., Patick, A. K., and Duggal, R. (2007). Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 51, 95-102.
28. Heck, J. A., Lam, A. M., Narayanan, N., and Frick, D. N. (2008). Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob. Agents Chemother. 52, 1901-1911.
29. Hiraga, N., Imamura, M., Abe, H., Nelson Hayes, C., Kono, T., Onishi, M., Tsuge, M., Takahashi, S., Ochi, H., Iwao, E., Kamiya, N., Yamada, I., et al. (2011). Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo. Hepatology 54, 781-788.
30. Houston, P., and Kodadek, T. (1994). Spectrophotometric assay for enzyme-mediated unwinding of double-stranded DNA. Proc. Natl. Acad. Sci. USA 91, 5471-5474.
31. Katsumata, K., Chono, K., Sudo, K., Shimizu, Y., Kontani, T., and Suzuki, H. (2011). Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes. Molecules 16, 7210-7223.
32. Kim, D. W., Gwack, Y., Han, J. H., and Choe, J. (1995). C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 215, 160-166.
33. Kleymann, G., Fischer, R., Betz, U. A., Hendrix, M., Bender, W., Schneider, U., Handke, G., Eckenberg, P., Hewlett, G., Pevzner, V., Baumeister, J., Weber, O., et al. (2002). New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392-398.
34. Kolykhalov, A. A., Mihalik, K., Feinstone, S. M., and Rice, C. M. (2000). Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3 nontranslated region are essential for virus replication in vivo. J. Virol. 74, 2046-2051.
35. Kwong, A. D., Rao, B. G., and Jeang, K. T. (2005). Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 4, 845-853.
36. Kyono, K., Miyashiro, M., and Taguchi, I. (1998). Detection of hepatitis C virus helicase activity using the scintillation proximity assay system. Anal. Biochem. 257, 120-126.
37. Lam, A. M., and Frick, D. N. (2006). Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 80, 404-411.
38. Lam, A. M., Keeney, D., Eckert, P. Q., and Frick, D. N. (2003). Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. J. Virol. 77, 3950-3961.
39. Lemon, S. M., McKeating, J. A., Pietschmann, T., Frick, D. N., Glenn, J. S., Tellinghuisen, T. L., Symons, J., and Furman, P. A. (2010). Development of novel therapies for hepatitis C. Antiviral Res. 86, 79-92.
40. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
41. Muramatsu, S., Ishido, S., Fujita, T., Itoh, M., and Hotta, H. (1997). Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization. J. Virol. 71, 4954-4961.
42. Murray, C. L., and Rice, C. M. (2011). Turning hepatitis C virus into a real virus. Annu. Rev. Microbiol. 65, 307-327.
43. Neumann-Haefelin, C., Frick, D. N., Wang, J. J., Pybus, O. G., Salloum, S., Narula, G. S., Eckart, A., Biezynski, A., Eiermann, T., Klenerman, P., Viazov, S., Roggendorf, M., et al. (2008). Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J. Virol. 82, 3438-3451.
44. Porter, D. J., Short, S. A., Hanlon, M. H., Preugschat, F., Wilson, J. E., Willard, D. H. J., and Consler, T. G. (1998). Product release is the major contributor to kcat for the hepatitis C virus helicase-catalyzed strand separation of short duplex DNA. J. Biol. Chem. 273, 18906-18914.
45. Preugschat, F., Averett, D. R., Clarke, B. E., and Porter, D. J. (1996). A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J. Biol. Chem. 271, 24449-24457.
46. Pyle, A. M. (2008). Translocation and unwinding mechanisms of RNA and DNA helicases. Annu. Rev. Biophys. 37, 317-336.
47. Raney, K. D., Sharma, S. D., Moustafa, I. M., and Cameron, C. E. (2010). Hepatitis C virus non-structural protein 3 (HCV NS3): A multifunctional antiviral target. J. Biol. Chem. 285, 22725-22731.
48. Rypma, R. S., Lam, A. M., and Frick, D. N. (2009). Effect of substrate traps on hepatitis C virus NS3 helicase catalyzed DNA unwinding: Evidence for enzyme catalyzed strand exchange. In "Bacterial DNA, DNA Polymerase and DNA Helicases," (W. D. Knudsen and S. S. Bruns, eds.), pp. 389-407. Nova Science Publishers, Inc., New York.
49. Suzich, J. A., Tamura, J. K., Palmer-Hill, F., Warrener, P., Grakoui, A., Rice, C. M., Feinstone, S. M., and Collett, M. S. (1993). Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J. Virol. 67, 6152-6158.
50. Tani, H., Akimitsu, N., Fujita, O., Matsuda, Y., Miyata, R., Tsuneda, S., Igarashi, M., Sekiguchi, Y., and Noda, N. (2009). High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem. Biophys. Res. Commun. 379, 1054-1059.
51. Tuteja, R. (2007). Helicases-Feasible antimalarial drug target for Plasmodium falciparum. FEBS J. 274, 4699-4704.
52. Tyagi, S., and Kramer, F. R. (1996). Molecular beacons: Probes that fluoresce upon hybridization. Nat. Biotechnol. 14, 303-308.
53. Yao, N., Hesson, T., Cable, M., Hong, Z., Kwong, A. D., Le, H. V., and Weber, P.C. (1997). Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol. 4, 463-467.
54. Yedavalli, V. S., Zhang, N., Cai, H., Zhang, P., Starost, M. F., Hosmane, R. S., and Jeang, K. T. (2008). Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication. J. Med. Chem. 51, 5043-5051.
55. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., Ferenci, P., Nevens, F., et al. (2011). Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428.
56. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73.